Compare Stocks: VERA, TGTX, CYTK, and ABVX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$88.61 -4.1%	$107.44	$69.81 ▼ $148.83	$7.76B	1.14	1.42 million shs	443,720 shs
CYTK Cytokinetics	$61.97 -3.1%	$70.48	$54.30 ▼ $88.31	$7.72B	0.41	2.13 million shs	192,245 shs
TGTX TG Therapeutics	$54.20 -3.2%	$54.18	$26.76 ▼ $59.30	$8.31B	1.8	2.13 million shs	427,420 shs
VERA Vera Therapeutics	$28.09 -1.7%	$32.46	$23.05 ▼ $56.05	$2.01B	1.06	1.62 million shs	153,473 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	+5.00%	+3.74%	-13.39%	-32.40%	-3.38%
CYTK Cytokinetics	+0.77%	+3.08%	-7.78%	-20.28%	+1.78%
TGTX TG Therapeutics	+3.00%	+4.99%	+5.58%	+2.06%	+59.77%
VERA Vera Therapeutics	+6.84%	-3.90%	-15.15%	-25.79%	-7.84%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$88.61 -4.1%	$107.44	$69.81 ▼ $148.83	$7.76B	1.14	1.42 million shs	443,720 shs
CYTK Cytokinetics	$61.97 -3.1%	$70.48	$54.30 ▼ $88.31	$7.72B	0.41	2.13 million shs	192,245 shs
TGTX TG Therapeutics	$54.20 -3.2%	$54.18	$26.76 ▼ $59.30	$8.31B	1.8	2.13 million shs	427,420 shs
VERA Vera Therapeutics	$28.09 -1.7%	$32.46	$23.05 ▼ $56.05	$2.01B	1.06	1.62 million shs	153,473 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	+5.00%	+3.74%	-13.39%	-32.40%	-3.38%
CYTK Cytokinetics	+0.77%	+3.08%	-7.78%	-20.28%	+1.78%
TGTX TG Therapeutics	+3.00%	+4.99%	+5.58%	+2.06%	+59.77%
VERA Vera Therapeutics	+6.84%	-3.90%	-15.15%	-25.79%	-7.84%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX Abivax	2.88	Moderate Buy	$156.69	76.84% Upside
CYTK Cytokinetics	2.86	Moderate Buy	$105.44	70.17% Upside
TGTX TG Therapeutics	2.56	Moderate Buy	$63.00	16.25% Upside
VERA Vera Therapeutics	2.80	Moderate Buy	$76.86	173.66% Upside

Current Analyst Ratings Breakdown

Latest VERA, TGTX, CYTK, and ABVX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/16/2026	CYTK Cytokinetics	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
10/15/2026	ABVX Abivax	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	CYTK Cytokinetics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	VERA Vera Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/14/2026	CYTK Cytokinetics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$104.00
10/12/2026	VERA Vera Therapeutics	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Market Perform	$34.00
10/8/2026	TGTX TG Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Buy (B-) ➝ Buy (B)
10/8/2026	CYTK Cytokinetics	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$112.00 ➝ $113.00
10/6/2026	TGTX TG Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
9/22/2026	ABVX Abivax	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$155.00 ➝ $151.00
9/22/2026	ABVX Abivax	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Neutral	$140.00 ➝ $118.00

(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX Abivax	N/A	N/A	N/A	N/A	$6.57 per share	N/A
CYTK Cytokinetics	$88.04M	87.58	N/A	N/A	($5.39) per share	-11.50
TGTX TG Therapeutics	$616.29M	13.46	$2.79 per share	19.40	$4.08 per share	13.28
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	$8.48 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX Abivax	-$380.27M	-$6.06	N/A	N/A	N/A	N/A	-91.69%	-71.96%	12/21/2026 (Estimated)
CYTK Cytokinetics	-$784.96M	-$7.22	N/A	N/A	N/A	-1,321.12%	N/A	-51.01%	11/4/2026 (Estimated)
TGTX TG Therapeutics	$447.18M	$2.74	19.81	20.45	2.30	55.22%	73.49%	34.14%	11/2/2026 (Estimated)
VERA Vera Therapeutics	-$299.61M	-$5.86	N/A	N/A	N/A	N/A	-84.13%	-66.79%	11/4/2026 (Estimated)

Latest VERA, TGTX, CYTK, and ABVX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	CYTK Cytokinetics	-$1.45	N/A	N/A	N/A	$40.61 million	N/A
11/4/2026	Q3 2026	VERA Vera Therapeutics	-$1.61	N/A	N/A	N/A	$3.90 million	N/A
11/2/2026	Q3 2026	TGTX TG Therapeutics	$0.3663	N/A	N/A	N/A	$245.47 million	N/A
9/21/2026	Q2 2026	ABVX Abivax	-$0.9170	-$1.71	-$0.7930	-$1.68	$0.80 million	$1.37 million
8/10/2026	Q2 2026	VERA Vera Therapeutics	-$1.58	-$1.52	+$0.06	-$1.52	$1.28 million	N/A
8/6/2026	Q2 2026	CYTK Cytokinetics	-$1.63	-$1.50	+$0.13	-$1.50	$17.59 million	$28.62 million
8/3/2026	Q2 2026	TGTX TG Therapeutics	$0.3057	$0.05	-$0.2557	$0.05	$229.77 million	$240.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX Abivax	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX Abivax	N/A	5.97	5.97
CYTK Cytokinetics	N/A	6.66	6.66
TGTX TG Therapeutics	1.23	4.27	3.72
VERA Vera Therapeutics	0.18	10.92	10.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX Abivax	47.91%
CYTK Cytokinetics	N/A
TGTX TG Therapeutics	58.58%
VERA Vera Therapeutics	99.21%

Insider Ownership

Company	Insider Ownership
ABVX Abivax	N/A
CYTK Cytokinetics	2.60%
TGTX TG Therapeutics	8.87%
VERA Vera Therapeutics	15.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX Abivax	80	87.53 million	N/A	Not Optionable
CYTK Cytokinetics	673	124.43 million	121.20 million	Optionable
TGTX TG Therapeutics	399	153.07 million	139.49 million	Optionable
VERA Vera Therapeutics	361	72.06 million	60.61 million	Optionable

VERA, TGTX, CYTK, and ABVX Headlines

Recent News About These Companies

Can Vera Therapeutics Stage Another Comeback?

October 14 at 12:50 PM | rttnews.com

Leerink Partners initiates coverage of Vera Therapeutics at market perform

October 13 at 2:58 PM | msn.com

Leerink Partners Initiates Vera Therapeutics at Market Perform With $34 Price Target

October 13 at 2:58 PM | finance.yahoo.com

Vera Therapeutics, Inc. (VERA) Stock Analysis: Unveiling a Potential 167% Upside in the Biotechnology Sector

October 13 at 2:58 PM | directorstalkinterviews.com

Vera Therapeutics (NASDAQ:VERA) Now Covered by Leerink Partners

October 12, 2026 | americanbankingnews.com

Leerink Partners Begins Coverage on Vera Therapeutics (NASDAQ:VERA)

October 12, 2026 | marketbeat.com

BofA Securities Adjusts Vera Therapeutics Price Target to $60 From $66, Maintains Buy Rating

October 9, 2026 | finance.yahoo.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Stock Has Consensus Target Price of $80.15

October 8, 2026 | americanbankingnews.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Stock Has Consensus Price Target of $80.15

October 8, 2026 | marketbeat.com

Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ...

October 5, 2026 | marketscreener.comM

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 2, 2026

October 5, 2026 | biospace.comB

Vera Therapeutics Announces Origin 3 Final Efficacy Analysis of TRUTAKNA in Iga Nephropathy Will Be A Featured Late-Breaking Oral Presentation At Asn Kidney Week 2026

October 3, 2026 | marketscreener.comM

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 2, 2026 | globenewswire.com

Vera Therapeutics to present ORIGIN 3 trial data at ASN Kidney Week

October 2, 2026 | streetinsider.com

Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the ...

October 2, 2026 | finance.yahoo.com

Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026

October 2, 2026 | globenewswire.com

Vera Therapeutics (NASDAQ:VERA) Shares Down 8.3% - Here's What Happened

September 23, 2026 | marketbeat.com

Insider Selling: Vera Therapeutics (NASDAQ:VERA) CEO Sells 18,500 Shares of Stock

September 18, 2026 | insidertrades.com

Analysts Offer Insights on Healthcare Companies: Viatris (VTRS) and Vera Therapeutics (VERA)

September 17, 2026 | theglobeandmail.com

Marshall Fordyce Sells 18,500 Shares of Vera Therapeutics (NASDAQ:VERA) Stock

September 17, 2026 | marketbeat.com

Vera Therapeutics (NASDAQ:VERA) Shares Up 7.8% - What's Next?

September 17, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VERA, TGTX, CYTK, and ABVX Company Descriptions

Abivax NASDAQ:ABVX

$88.61 -3.77 (-4.08%)

As of 11:41 AM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Cytokinetics NASDAQ:CYTK

$61.96 -1.96 (-3.06%)

As of 11:41 AM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

TG Therapeutics NASDAQ:TGTX

$54.20 -1.81 (-3.22%)

As of 11:41 AM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Vera Therapeutics NASDAQ:VERA

$28.08 -0.49 (-1.70%)

As of 11:41 AM Eastern

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VERA, TGTX, CYTK, and ABVX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VERA, TGTX, CYTK, and ABVX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VERA, TGTX, CYTK, and ABVX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VERA, TGTX, CYTK, and ABVX Company Descriptions

Abivax NASDAQ:ABVX

Cytokinetics NASDAQ:CYTK

TG Therapeutics NASDAQ:TGTX

Vera Therapeutics NASDAQ:VERA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VERA, TGTX, CYTK, and ABVX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VERA, TGTX, CYTK, and ABVX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VERA, TGTX, CYTK, and ABVX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VERA, TGTX, CYTK, and ABVX Company Descriptions

Abivax NASDAQ:ABVX

Cytokinetics NASDAQ:CYTK

TG Therapeutics NASDAQ:TGTX

Vera Therapeutics NASDAQ:VERA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools